logo
U.S. birth rate hits all-time low, CDC data shows

U.S. birth rate hits all-time low, CDC data shows

CBS News5 days ago
New York — The fertility rate in the U.S. dropped to an all-time low in 2024 with fewer than 1.6 kids per woman, federal data released Thursday shows.
The U.S. was once among only a few developed countries with a rate that ensured each generation had enough children to replace itself - about 2.1 kids per woman. But it has been sliding in America for close to two decades as more women are waiting longer to have children or never taking that step at all.
The new statistic is on par with fertility rates in western European countries, according to World Bank data.
Alarmed by recent drops, the Trump administration has taken steps to increase falling birth rates, like issuing an executive order in February meant to expand access to and reduce costs of in vitro fertilization and backing the idea of "baby bonuses" that might encourage more couples to have kids.
White House staff secretary Will Scharf remarked to reporters at the time that in vitro treatments "have become unaffordable for many Americans or been unaffordable for many Americans." Health insurance companies aren't required to cover IVF treatments, which can cost tens of thousands of dollars.
But there's no reason to be alarmed, according to Leslie Root, a University of Colorado Boulder researcher focused on fertility and population policy.
"We're seeing this as part of an ongoing process of fertility delay. We know that the U.S. population is still growing, and we still have a natural increase - more births than deaths," she said.
The U.S. Centers for Disease Control and Prevention released the statistic for the total fertility rate with updated birth data for 2024.
In the early 1960s, the U.S. total fertility rate was around 3.5, but plummeted to 1.7 by 1976 after the Baby Boom ended. It gradually rose to 2.1 in 2007 before falling again, aside from a 2014 uptick. The rate in 2023 was 1.621 but inched down in 2024 to 1.599, according to the CDC's National Center for Health Statistics.
Birth rates are generally declining for women in most age groups - and that doesn't seem likely to change in the near future, said Karen Guzzo, director of the Carolina Population Center at the University of North Carolina.
People are marrying later and also worried about their ability to have the money, health insurance and other resources needed to raise children in a stable environment.
"Worry is not a good moment to have kids," and that's why birth rates in most age groups are not improving, she said.
Asked about birth-promoting measures outlined by the Trump administration, Guzzo said they don't tackle larger needs like parental leave and affordable child care.
"The things that they are doing are really symbolic and not likely to budge things for real Americans," she said.
The CDC's new report, which is based on a more complete review of birth certificates than provisional data released earlier this year, also showed a 1% increase in births - about 33,000 more - last year compared to the prior year.
That brought the yearly national total to just over 3.6 million babies born.
But this is different: The provisional data indicated birth rate increases last year for women in their late 20s and 30s. However, the new report found birth rate declines for women in their 20s and early 30s, and no change for women in their late 30s.
What happened? CDC officials said it was due to recalculations stemming from a change in the U.S. Census population estimates used to compute the birth rate.
That's plausible, Root said. As the total population of women of childbearing age grew due to immigration, it offset small increases in births to women in those age groups, she said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

Yahoo

time5 hours ago

  • Yahoo

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit Contacts:Suzanne Harnettsharnett@ and Investors Media Jennifer Drew-Bear, Edison GroupJdrew-bear@ Holly Stevens, CG Lifehstevens@

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

Yahoo

time5 hours ago

  • Yahoo

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

(Reuters) -Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and decreases the risk of market withdrawal. The company said on Monday it would resume shipments of Elevidys — approved in the U.S. to treat a rare condition called Duchenne muscular dystrophy — to patients who can walk. U.S. shipments to patients who cannot walk independently are still halted, following the death of two teenage boys earlier this year. These incidents brought heightened regulatory scrutiny to Sarepta in recent weeks, while the pause of shipments raised concerns about the future of Elevidys — the company's largest revenue generator. Sarepta's announcement followed the U.S. Food and Drug Administration's recommendation that the voluntary hold on shipments be removed after a probe showed the death of an 8-year-old boy in Brazil was not related to Elevidys. Wall Street analysts said the resumption of shipments would allow Sarepta to fulfill its near-term payments to partner Arrowhead and maintain access to its debt facilities. "The FDA's recommendation and the resumption of commercial treatment in the U.S. virtually eliminate the risk of Elevidys being formally withdrawn from the market," said William Blair analyst Sami Corwin. While the decision allows some patients to regain access to the treatment, analysts warned that patients and doctors could show hesitancy in light of the recent hit to reputation. "It remains to be seen how the news headlines regarding the patient deaths will affect commercial interest in the near term," Corwin said. Sarepta's partner Roche had also stopped Elevidys shipments in certain countries outside the U.S. Shares of Sarepta surged 36% to $18.85 in premarket trading. They have fallen more than 80% since the first Elevidys-related death was reported in March. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Sweeping Problems Under The Rug By The Feds Doesn't Make Them Go Away
Sweeping Problems Under The Rug By The Feds Doesn't Make Them Go Away

Forbes

time5 hours ago

  • Forbes

Sweeping Problems Under The Rug By The Feds Doesn't Make Them Go Away

A man walks his dog past a homeless man sleeping under a message painted on a boarded up shop in San ... More Francisco, California on April, 1, 2020, during the novel coronavirus outbreak. - The US death toll from the coronavirus pandemic topped 5,000 late on April 1, according to a running tally from Johns Hopkins University. (Photo by Josh Edelson / AFP) (Photo by JOSH EDELSON/AFP via Getty Images) For decades, every administration, every Congress, put many things off for someone else to deal with. No one can get everything done all the time, that's understandable. But many current economic and social programs aren't a result of juggling what might be possible. Instead, they have become the ultimate attempt to kick every can down the road. That doesn't solve problems. It only hides them and allows them to grow and fester. One of the current examples is homelessness. Here is a statement out of the presidential executive order, Ending Crime And Disorder On America's Streets: 'The overwhelming majority of these individuals are addicted to drugs, have a mental health condition, or both. Nearly two-thirds of homeless individuals report having regularly used hard drugs like methamphetamines, cocaine, or opioids in their lifetimes. An equally large share of homeless individuals reported suffering from mental health conditions.' Homelessness is a problem in many parts of the country. And, yes, people on the streets are often troubled in one way or another. However, the entire executive order is a rhetorical setup, claiming that 'nearly two-thirds' of the individuals reporting having used 'hard drugs like methamphetamines, cocaine, or opioids in their lifetimes.' No source for the statistic that is then delivered to deemphasize that any such use might have been long before. And then a statement that an 'equally large share of homeless individuals reported suffering from mental health conditions.' No source, again, and no explanation of what mental health conditions mean. Broadly defined enough, like any amount of depression, anxiety, discomfort, and so on, it could include everyone in the country. Next, a combination of claiming that spending by the federal government and states has run tens of billions on failed programs 'that address homelessness but not its root causes.' After claiming that homeless people leave 'other citizens vulnerable to public safety threats' comes the statement, 'Shifting homeless individuals into long-term institutional settings for humane treatment through the appropriate use of civil commitment will restore public order.' After stating that previous spending never looked at root causes, presuming that the administration knows the root causes, the proffered solution is to lock people away. The message is to ignore the problem and put it out of sight. The point isn't really for safety, because most dangerous behavior in the country doesn't come from homeless people. It's for comfort and to pretend everything is fine. This has economic and social implications. Institutionalize where? Privately owned prisons where someone makes a lot of money from incarcerations? Hospitals that have been financially struggling but will even more now that Medicaid has been so thoroughly cut? Similar issues come in arguments over diversity, equity, and inclusion, or DEI. The administration wants it purged not only from websites and government discussions, but from corporations, universities, and anywhere else the term might appear. Again, the communication expressed by action is to strike any mention of the topic anywhere, to bury it from consciousness as though that makes issues go away. It never does. Other parts of life are no different. Corporations want to promote the use of the most recent forms of artificial intelligence. Traditionally, the argument executives would use is not that technology was about enabling job cuts, but to free people up to do more useful and interesting work. That mask has finally begun to slip as CEOs and their corporations boast of shrinking their workforces. Ultimately, this will lead to fewer people being employed, greater degrees of consumer financial struggle, and economic weakness. But, again, that all gets brushed under the carpet. No society can long stand with such undermining. So long as problems are ignored, they likely grow worse until there comes a point that they demand more resources than are available.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store